The fastest proposal follow-up can also be the easiest place to overstate what the platform will deliver.
Enterprise buyers need a timely, tailored point of view while sellers must protect clinical and commercial commitments.
Who you’d be doing this for
“My CFO asked what we’d actually be buying, and I still had three different answers after the follow-up call.”
Ines Ricci · Population Health Manager
Evaluates virtual-care vendors for an Enterprise employer population and must recommend a program to benefits and finance leaders.
What is at stake
Enterprise opportunities are waiting on tailored follow-up while sellers rebuild discovery context and verify claims. You must decide what AI can prepare and what a seller must review before anything reaches a buyer.
Why it isn’t already fixed
Every obvious fix costs something else. That’s the part you’d have to decide.
- follow-up speed vs. claim verification
- seller ownership vs. draft consistency
- pipeline movement vs. forecast integrity
- clinical evidence vs. tailored positioning
Why Omada Health
Omada Platform sales depend on translating cardiometabolic and GLP-1 care into evidence a population health manager can trust.
Written with these in mind
Not your kind of problem? 7 more at Omada Health, or browse every organization.
This is the setup. The work is inside.
Running it puts you in the room: the full situation and its constraints, stakeholders who push back in their own words, and the decisions that are yours to make. What you produce becomes a Day One Plan — work you can show someone instead of describing.